What happens when a 60-year-old frontline charity decides not only to support families but also to invest in startups?
For more than six decades, Young Lives vs Cancer has supported children and families navigating cancer. Through its frontline workers embedded across NHS pathways, the organisation has developed a rare perspective on how paediatric cancer care actually functions: the clinical structures, the safeguarding requirements, and the psychosocial gaps that often remain invisible to policymakers and investors.
Andreas speaks with Helen McShane, who leads the Innovation Lab at Young Lives vs Cancer, and Zoe Peden, Partner at impact venture firm Ananda. Helen brings the institutional lens—how a charity embedded in healthcare systems approaches innovation and system change—while Zoe chairs the Lab’s investment committee and contributes venture discipline, from governance and portfolio thinking to evaluating early-stage opportunities.
Together, they explore why the charity has begun experimenting with a new role inside the healthcare innovation ecosystem: deploying capital alongside its institutional expertise.
Proximity to the system inevitably leads to pattern recognition. Over time, Young Lives vs Cancer began to see that many persistent challenges facing young cancer patients were not problems of intent but of innovation and adoption. Digital tools existed. Founders were building solutions. Yet early-stage companies often struggled to navigate the complexity of healthcare institutions and clinical environments.
Through its Innovation Lab, the charity is now testing a new model: supporting startups not only through partnerships but also through targeted investment.
What’s Covered in This Episode
00:00 — Why a charity would start investing in startups
How frontline experience led Young Lives vs Cancer to explore venture-backed innovation.
03:00 — The concept of mission capital
Why charities can support startups in ways traditional investors cannot.
06:30 — Why a £30k investment still matters
How credibility, partnerships, and institutional access create value beyond cheque size.
10:00 — Building venture governance inside a charity
Aligning boards, leadership, and investment discipline.
14:00 — The barriers facing healthcare startups
Safeguarding, procurement, and the realities of NHS adoption.
19:00 — The long-term ambition for the Innovation Lab
What success could look like five years from now.
Mission Capital
The Innovation Lab’s first investment—£30,000 into Little Journey, a digital platform helping children prepare for hospital procedures—illustrates the approach.
The value of the partnership extends far beyond the cheque itself. Young Lives vs Cancer brings assets that traditional venture investors cannot replicate: frontline insight into patient needs, safeguarding expertise, trusted relationships with families, and credibility inside NHS cancer pathways.
Those assets can significantly reduce the barriers that healthcare startups face when attempting to move from product development to real-world adoption.
For founders building in paediatric healthcare, that combination of institutional access and lived-experience insight can be as valuable as capital itself.
Why Healthcare Innovation Needs Institutional Partners
Healthcare innovation often stalls not because products fail but because systems resist change.
Startups entering clinical environments must navigate safeguarding requirements, privacy standards, procurement frameworks, and the operational realities of healthcare providers. Even promising technologies can struggle to gain traction without trusted partners who understand how those systems work.
Mission-driven organisations such as Young Lives vs Cancer sit in a unique position. Their institutional knowledge, patient relationships, and credibility with clinicians allow them to act as bridges between startups and healthcare infrastructure.
The Innovation Lab attempts to translate those advantages into a practical model for supporting innovation.
A New Interface Between Charity and Venture
Young Lives vs Cancer is only beginning to explore this approach, but the implications extend beyond a single investment.
Charities hold unique assets: domain expertise, trusted relationships with communities, and institutional credibility inside systems that are often difficult for startups to enter. Venture capital brings capital discipline, portfolio thinking, and the ability to scale new solutions.
The experiment is still early, but it signals how mission-driven institutions and venture capital may increasingly converge to unlock innovation in complex systems like healthcare.
